HBV replication inhibitors

• Published in: Antiviral research Vol. 179; p. 104815
• Main Authors: Pierra Rouviere, Claire, Dousson, Cyril B., Tavis, John E.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01-07-2020
• Subjects: Animals; Antiviral Agents - pharmacology; Chronic hepatitis B; Clinical Trials as Topic; Hepatitis B virus; Hepatitis B virus - drug effects; Hepatitis B virus - physiology; Hepatitis B, Chronic - drug therapy; Hepatitis B, Chronic - virology; Humans; Mice; Nucleic Acid Synthesis Inhibitors - pharmacology; Nucleos(t)ide analogs; Nucleosides - pharmacology; Reverse transcriptase inhibitors; Ribonuclease H - antagonists & inhibitors; Ribonuclease H inhibitors; Virus Replication - drug effects; Reverse transcriptase inhibitors; Ribonuclease H inhibitors; Hepatitis B virus; Chronic hepatitis B; Nucleos(t)ide analogs
• ISSN: 0166-3542; 1872-9096
• DOI: 10.1016/j.antiviral.2020.104815

Chronic Hepatitis B Virus infections afflict >250 million people and kill nearly 1 million annually. Current non-curative therapies are dominated by nucleos(t)ide analogs (NAs) that profoundly but incompletely suppress DNA synthesis by the viral reverse transcriptase. Residual HBV replication during NA therapy contributes to maintenance of the critical nuclear reservoir of the HBV genome, the covalently-closed circular DNA, and to ongoing infection of naive cells. Identification of next-generation NAs with improved efficacy and safety profiles, often through novel prodrug approaches, is the primary thrust of ongoing efforts to improve HBV replication inhibitors. Inhibitors of the HBV ribonuclease H, the other viral enzymatic activity essential for viral genomic replication, are in preclinical development. The complexity of HBV's reverse transcription pathway offers many other potential targets. HBV's protein-priming of reverse transcription has been briefly explored as a potential target, as have the host chaperones necessary for function of the HBV reverse transcriptase. Improved inhibitors of HBV reverse transcription would reduce HBV's replication-dependent persistence mechanisms and are therefore expected to become a backbone of future curative combination anti-HBV therapies.
•NA inhibitors currently dominate HBV therapy.•Improvement of NAs focuses on efficacy, safety, resistance and prodrug delivery.•HBV ribonuclease inhibitors are in preclinical development.•Other approaches for directly inhibiting HBV reverse transcription are possible.